NYU Finds Way to Reduce Opioid Tolerance in Cancer Patients

Oral cancer patients facing unbearable pain may soon have a safer way to find relief, thanks to researchers who discovered how to prevent the body from growing resistant to painkillers.

Scientists at NYU College of Dentistry found that blocking a specific protein called EGFR can reduce both cancer pain and the tolerance patients develop to opioids like morphine. This matters because oral cancer causes some of the most severe pain of any cancer type, making it difficult for patients to eat, drink, or even speak with loved ones.

The research team studied human tissue samples and found that oral cancer cells produce extremely high levels of EGFR, a protein that normally regulates cell growth. When cancer causes EGFR to go into overdrive, it triggers painful tumor growth in the tongue and mouth while simultaneously making pain medication less effective over time.

Testing on mice with oral cancer confirmed what the researchers hoped. Inhibiting EGFR didn't just slow cancer growth. It also decreased pain levels and prevented the animals from developing tolerance to their pain medication.

Associate Professor Yi Ye, who led the study, emphasized that oral cancer creates a particularly cruel situation for patients. Tumors growing in the mouth and tongue make even basic daily activities agonizing, yet the very medications meant to provide relief often stop working as the body adapts to them.

The Bright Side

The most exciting part of this discovery is that doctors won't need to wait years for new treatments to reach patients. EGFR-inhibiting drugs like cetuximab are already FDA-approved and routinely used as cancer therapy, meaning the safety profile is well-established.

These medications are currently prescribed as add-on treatments for oral cancer patients. Future clinical trials could now test whether they also help manage pain and prevent opioid tolerance, potentially offering a dual benefit with minimal additional risk.

Ye noted that because these drugs are already available and proven safe, they could be rapidly repurposed if trials confirm they benefit patients struggling with pain management. This means oral cancer patients might access this treatment much sooner than if researchers were starting from scratch with an entirely new drug.

The findings offer real hope for people facing one of the most painful cancer diagnoses while navigating the nationwide struggle with opioid dependence and tolerance.